Table of Contents

• 1.1 List of Tables 5
• 1.2 List of Figures 7

2 Introduction 8

• 2.1 Reproductive Hormones and Proteins Tests Overview 8

3 Products under Development 9

• 3.1 Reproductive Hormones and Proteins Tests - Pipeline Products by Stage of Development 9
• 3.2 Reproductive Hormones and Proteins Tests - Pipeline Products by Segment 10
• 3.3 Reproductive Hormones and Proteins Tests - Pipeline Products by Territory 11
• 3.4 Reproductive Hormones and Proteins Tests - Pipeline Products by Regulatory Path 12
• 3.5 Reproductive Hormones and Proteins Tests - Pipeline Products by Estimated Approval Date 13

4 Reproductive Hormones and Proteins Tests - Pipeline Products under Development by Companies 14

• 4.1 Reproductive Hormones and Proteins Tests Companies - Pipeline Products by Stage of Development 14
• 4.2 Reproductive Hormones and Proteins Tests - Pipeline Products by Stage of Development 16

5 Reproductive Hormones and Proteins Tests Companies and Product Overview 18

• 5.1 AgPlus Diagnostics LTD Company Overview 18
  • 5.1.1 AgPlus Diagnostics LTD Pipeline Products & Ongoing Clinical Trials Overview 18
• 5.2 Albert Einstein College of Medicine Company Overview 19
  • 5.2.1 Albert Einstein College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 19
• 5.3 Aura Biotechnologies Pvt Ltd Company Overview 20
  • 5.3.1 Aura Biotechnologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
• 5.4 Beckman Coulter Inc Company Overview 21
  • 5.4.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 21
• 5.5 Boditech Med Inc Company Overview 22
  • 5.5.1 Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 22
• 5.6 Bruyere Research Institute Company Overview 23
  • 5.6.1 Bruyere Research Institute Pipeline Products & Ongoing Clinical Trials Overview 23
• 5.7 China Medical Technologies Inc (Inactive) Company Overview 24
  • 5.7.1 China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24
• 5.8 DiaSorin SpA Company Overview 25
  • 5.8.1 DiaSorin SpA Pipeline Products & Ongoing Clinical Trials Overview 25
• 5.9 Ellume Ltd Company Overview 27
  • 5.9.1 Ellume Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
• 5.10 Fujirebio Diagnostics Inc Company Overview 28
  • 5.10.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 28
• 5.11 Genovum Sp. z o.o. Company Overview 31
  • 5.11.1 Genovum Sp. z o.o. Pipeline Products & Ongoing Clinical Trials Overview 31
• 5.12 Hebrew University of Jerusalem Company Overview 32
  • 5.12.1 Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 32
• 5.13 Immunodiagnostic Systems Holdings plc Company Overview 34
  • 5.13.1 Immunodiagnostic Systems Holdings plc Pipeline Products & Ongoing Clinical Trials Overview 34
• 5.14 King's College London Company Overview 36
  • 5.14.1 King's College London Pipeline Products & Ongoing Clinical Trials Overview 36
• 5.15 Labsystems Diagnostics Oy Company Overview 37
  • 5.15.1 Labsystems Diagnostics Oy Pipeline Products & Ongoing Clinical Trials Overview 37
• 5.16 Lucine Biotechnology, Inc. Company Overview 38
  • 5.16.1 Lucine Biotechnology, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
• 5.17 Northwestern University Company Overview 39
  • 5.17.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 39
• 5.18 Paramedical Srl Company Overview 41
  • 5.18.1 Paramedical Srl Pipeline Products & Ongoing Clinical Trials Overview 41
• 5.19 PerkinElmer Inc Company Overview 42
  • 5.19.1 PerkinElmer Inc Pipeline Products & Ongoing Clinical Trials Overview 42
• 5.20 Proteomika (Inactive) Company Overview 43
  • 5.20.1 Proteomika (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 43
• 5.21 QuickCheck Health Inc Company Overview 44
  • 5.21.1 QuickCheck Health Inc Pipeline Products & Ongoing Clinical Trials Overview 44
• 5.22 redhot diagnostics AB Company Overview 45
  • 5.22.1 redhot diagnostics AB Pipeline Products & Ongoing Clinical Trials Overview 45
• 5.23 Roche Diagnostics International Ltd Company Overview 46
  • 5.23.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
• 5.24 Shahid Beheshti University Company Overview 48
  • 5.24.1 Shahid Beheshti University Pipeline Products & Ongoing Clinical Trials Overview 48
• 5.25 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 49
  • 5.25.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 49
• 5.26 Siemens Healthcare Diagnostics Inc Company Overview 53
  • 5.26.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 53
• 5.27 Siemens Healthineers AG Company Overview 58
  • 5.27.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 58
• 5.28 SomaLogic Inc Company Overview 61
  • 5.28.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 61
• 5.29 Swan Diagnostics Ltd Company Overview 62
  • 5.29.1 Swan Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 62
• 5.30 Sysmex Corp Company Overview 63
  • 5.30.1 Sysmex Corp Pipeline Products & Ongoing Clinical Trials Overview 63
• 5.31 Thermo Fisher Scientific Inc Company Overview 65
  • 5.31.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 65
• 5.32 University of Edinburgh Company Overview 66
  • 5.32.1 University of Edinburgh Pipeline Products & Ongoing Clinical Trials Overview 66
• 5.33 University of Otago Company Overview 67
  • 5.33.1 University of Otago Pipeline Products & Ongoing Clinical Trials Overview 67

6 Reproductive Hormones and Proteins Tests- Recent Developments 68

• 6.1 Oct 30, 2019: Quidel reports third quarter 2019 financial results 68
• 6.2 Oct 30, 2019: PerkinElmer announces financial results for the third quarter of 2019 69
• 6.3 Oct 23, 2019: bioMerieux - Third-Quarter 2019 Business Review 70
• 6.4 Oct 22, 2019: bioMerieux - Third quarter 2019 business review 72
• 6.5 Oct 16, 2019: Abbott reports third-quarter 2019 results 73
• 6.6 Oct 16, 2019: Biomerica reports 1st quarter fiscal 2020 financials 76

7 Appendix 132

• 7.1 Methodology 132
• 7.2 About GlobalData 135
• 7.3 Contact Us 135

Reproductive Hormones and Proteins Tests - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, “Reproductive Hormones and Proteins Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Reproductive Hormones and Proteins Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Reproductive Hormones and Proteins Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Reproductive Hormones and Proteins Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Reproductive Hormones and Proteins Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Reproductive Hormones and Proteins Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date